Clinical trial Recruiting at 1 site Observational Ages 18 and up

Using radiofrequency ablation to treat indeterminate thyroid nodules

Official title: Radiofrequency Ablation for Indeterminate Bethesda III Thyroid Nodules

Run by Columbia University · NCT05189808 · Data updated 2026-11-12

This study is testing whether using radiofrequency ablation can safely treat certain thyroid nodules without the need for surgery.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment50 (estimated)
SponsorColumbia University
Academic / other
Locations1 site (New York, New York)
StatusRecruiting
StartedAugust 1, 2020
Main results expectedAugust 2027
Study endsAugust 2028
Registry record updatedMay 29, 2026
Trial IDNCT05189808 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are patients with indeterminate Bethesda III thyroid nodules that have been molecularly profiled as benign.

Probably not a fit

Patients with cardiac arrhythmias or those who are pregnant will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the efficacy and safety of radiofrequency ablation (RFA) for treating indeterminate Bethesda III thyroid nodules. It involves a chart review where patient data is collected before and after the RFA procedure, which uses image guidance to deliver high-frequency electrical currents to the nodules, generating heat to treat them. The study aims to provide insights into the outcomes of RFA, potentially reducing unnecessary surgeries for patients with benign nodules.

Why it matters

Potential benefit: If successful, this approach could reduce the need for surgical interventions in patients with indeterminate thyroid nodules, minimizing risks and complications.

How similar studies have gone: Other studies have shown promising results with radiofrequency ablation for thyroid nodules, indicating that this approach is gaining traction in clinical practice.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Indeterminate Bethesda III nodules that have been molecularly profiled benign with either Afirma Genomic Sequencing Classifier (GSC) or ThyroSeq v3 tests

Exclusion Criteria:

* cardiac arrthymias
* pregnancy

Where it's running

  • Columbia University
    New York, New York, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.